DNA synthesis inhibitors: Fluoroquinolones

27,495views

DNA synthesis inhibitors: Fluoroquinolones

BIIC

BIIC

Anemia of chronic disease
Lead poisoning
Vitamin B12 deficiency
Macrocytic anemia: Pathology review
Megaloblastic anemia
Microcytic anemia: Pathology review
Beta-thalassemia
Alpha-thalassemia
Hereditary spherocytosis
Sickle cell disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pyruvate kinase deficiency
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Hemophilia
Antithrombin III deficiency
Protein C deficiency
Vitamin K deficiency
Von Willebrand disease
Bernard-Soulier syndrome
Glanzmann's thrombasthenia
Hemolytic-uremic syndrome
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Factor V Leiden
Protein S deficiency
Antiphospholipid syndrome
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Polycythemia vera (NORD)
Essential thrombocythemia (NORD)
Blood groups and transfusions
Thymus histology
Spleen histology
Lymph node histology
Contracting the immune response and peripheral tolerance
Sepsis
Autoimmune hemolytic anemia
Staphylococcus epidermidis
Enterococcus
Streptococcus pneumoniae
Escherichia coli
Klebsiella pneumoniae
Enterobacter
Protein synthesis inhibitors: Aminoglycosides
Mechanisms of antibiotic resistance
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
Miscellaneous cell wall synthesis inhibitors
DNA synthesis inhibitors: Fluoroquinolones
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Blood products and transfusion: Clinical
Salmonella typhi (typhoid fever)
Borrelia burgdorferi (Lyme disease)
Leptospira
Borrelia species (Relapsing fever)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Ehrlichia and Anaplasma
Yellow fever virus
Dengue virus
Zika virus
West Nile virus
Plasmodium species (Malaria)
Antimalarials
Babesia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelofibrosis (NORD)
Myelodysplastic syndromes
Lymphomas: Pathology review
Leukemias: Pathology review
Wiskott-Aldrich syndrome
Ataxia-telangiectasia
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Giardia lamblia
Entamoeba histolytica (Amebiasis)
Toxoplasma gondii (Toxoplasmosis)
Trypanosoma cruzi (Chagas disease)
Leishmania
Trypanosoma brucei
Strongyloides stercoralis
Wuchereria bancrofti (Lymphatic filariasis)
DNA synthesis inhibitors: Metronidazole
Antimetabolites: Sulfonamides and trimethoprim
Plasma cell disorders: Pathology review
HIV (AIDS)

Transcript

Watch video only

Content Reviewers

Our bodies consist of eukaryotic cells, while bacterias consist of prokaryotic cells.

So, in order to treat bacterial infections we can develop antimicrobials that only target prokaryotic cells while leaving our cells mostly unharmed.

One of these targets is bacterial DNA, and we call these medications DNA inhibitors or nucleic acid inhibitors.

There are plenty of processes and enzymes involved that we can target and the quinolones and fluoroquinolones inhibit an enzyme called DNA topoisomerase.

So there are many different types of topoisomerases but we’ll be looking at topoisomerase II, also called DNA gyrase, and topoisomerase IV.

Both types of topoisomerases cause double strand breaks in DNA, but at different points during mitosis.

Topoisomerase II plays a role in condensing the chromosomes by making a double strand break in the DNA so that it can be more tightly wound, causing a supercoil.

When enough supercoils are induced, the DNA condenses.

Topoisomerase IV plays a role later on, after the chromosome has been replicated, where it causes a double strand break in the DNA so the new DNA strand can be disentangled from the original.

Now, quinolones are created to target bacterial topoisomerases, but it was soon discovered that by adding a fluorine molecule to the quinolones, they become more effective.

So these newer medications, called fluoroquinolones, replaced the older quinolones in most clinical settings.

Common fluoroquinolones include ciprofloxacin, ofloxacin, balofloxacin, levofloxacin, gemifloxacin, and moxifloxacin.

One way to tell a fluoroquinolone apart from other antimicrobials is that they all have the suffix “-floxacin.”

These medications can be taken peroral or via IV, but ciprofloxacin and ofloxacin are also available in otic formulations, while moxifloxacin is also available in ophthalmic solutions.

Now fluoroquinolones are broad spectrum bactericidal antibiotics and ciprofloxacin in particular is widely used.

They are very effective against gram negative bacterias like Enterobacteriaceae, Haemophilus, Legionella, Neisseria, Moraxella, and even Pseudomonas species.

They are also effective against certain mycobacteria and can be used for the treatment of tuberculosis.

However, more and more bacteria are becoming resistant to ciprofloxacin, either through mutations in the genes that code of topoisomerases, or through efflux pumps that pump the medication out.

Another downside is that the older fluoroquinolones are less effective against Gram positive bacteria, but the newer ones, like levofloxacin, gemifloxacin, and moxifloxacin, have improved effectiveness against Gram positive cocci, especially Streptococcus pneumoniae, so they are called respiratory fluoroquinolones since they are often used to treat hospital acquired pneumonia.

The trade off is that they are less effective against pseudomonas than ciprofloxacin.

Most fluoroquinolones are not effective against MRSA.

As a general rule, fluoroquinolones should not be taken perorally together with mineral supplements like iron, zinc, or calcium pills.

They’ll bind to each other, a process called chelation, preventing their absorption from the gut.

They are metabolized in the liver by a family of enzymes called cytochrome p450, but they are also inhibitors of this enzyme.

For side effects, fluoroquinolones can cause tendonitis especially in the achilles tendon, where they can cause it to rupture.

Due to this, they should not be used by active athletes and the elderly.